Smarter leaders trust GlobalData

Premium Insights Genomics in pharma: gene silencing

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Pfizer Inc

Amgen Inc

Moderna Inc

Otsuka Holdings Co Ltd

Regeneron Pharmaceuticals Inc

View all

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Gene silencing is a key innovation area in genomics

Gene silencing is generally defined as an epigenetic modification of gene expression leading to inactivation of previously active individual genes at transcriptional or translational levels or larger chromosome regions. It is a relatively new treatment technique that makes use of the body’s natural processes to control disease by suppressing or ‘silencing’ specific genes that are associated with certain diseases. This approach can be used for therapeutic purposes to treat various diseases ranging from cancer to infectious and immune disorders.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 260+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of gene silencing.

Key players in gene silencing – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to gene silencing

Pfizer is one of the leading patent filers in gene silencing. The company discovers, develops, manufactures, and commercializes biopharmaceuticals. It offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. Pfizer is involved in the development of several oligonucleotides and RNA-based drug candidates, which show the therapeutic intervention by a gene silencing mechanism of action. Aceragen and Curevac are some of the other key patent filers in gene silencing.

In terms of application diversity, Tallac Therapeutics leads the pack, while Amgen and Regeneron Pharmaceuticals stood in the second and third positions, respectively. By means of geographic reach, Moderna held the top position, followed by Otsuka Holdings Co Ltd and Regulus Therapeutics.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Genomics.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.